The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
We are unfortunate that the IFRS 15 contract revenue restatement to gross up both revenue and costs has partially obscured a very good H1 result. Reported net revenue in H1 2017 was £6m, which was after a commission share of £4.5m was paid, this has now been grossed up to £10.5m. So in reality, we have seen net revenue growth of circa 55%. I am very frustrated that this hasn’t been made clearer in the RNS! Nevertheless, very good progress on the road to breakeven, and our cash balance remains solid with only £700k outflow in H1. I just hope new and existing investors aren’t misled by the false fall in net revenue, and the lack of clarity on margins etc. It’s a lot better than the headline figures show!
Why would that have any impact on the current price? It’s not as if she is going to start offloading her stake... Need to look at the bigger picture here!
Brainer, can you explain why you were ramping Okyo Pharma to high heaven last weekend (a pump which has a mcap of 28m that appears to have no justification at all), yet are so scathing of IMTK? Smacks of jealousy to me. IMTK looks a bargain at this price and I’ll be buying in Monday morning - huge potential upside!
From the outside looking in, it seems as if Tlou’s future is reliant on the Botswanan government choosing it over a local company... The other company being invited to re-tender is a local Botswana company Sekaname (PTY) Ltd. Surely until this tender is granted this is about as a big a gamble as you could find?
Hi Vitali, Great post as always! Following on from this I did some very brief research and found the following article dated 13th July that states one publisher expects to make $10m from the ad breaks program in 2018 and several publishers over $1m. Unclear if this article could relate to BB or is just US domiciled publishers, but shows the potential as you say... https://digiday.com/media/facebook-video-ad-breaks-signs-of-life/ Furthermore, page 5 of our 2017 annual report has the following quote; ‘Our Q4 platform advertising revenues benefitted heavily from our entry to the Facebook ‘ad breaks’ beta testing.’ There is no breakdown of how much revenue was actually generated via ad breaks in Q4, but the above comment suggests it could have been material, as in a few hundred thousand at least? As such I’m very intrigued to discover the H1 revenues given the spectacular viewing figures achieved. The Digiday article adds even more intrigue, we can but hope the numbers deliver!
Definitely seem to have formed a solid base at 1.50 and is now starting to build :) Big thanks to all of the thoughtful discussion below this week, hopefully help bring some new investors on board before the interims. Another positive that I haven’t seen discussed is the fact they cancelled a £2m overdraft facility in Feb 18 as it was deemed unnneccessary due to their cash position - got to mean breakeven was very close!
Advertised spread of 22% is crazy, actual spread currently 1.755 - 1.86 and slowly narrowing. Interesting times ahead I feel.
Terrific news, the ability to attract industry leading figures illustrates we are going places IMO. This also seems to prove that yesterday’s sudden surge of buying wasn’t down to technicals, but more the fact this news leaked...
Wow, thanks for that insightful contribution such! There hasn’t been any ramping in here, merely stating that those who have patience will stand much more chance of making money here. @Vitali, I’ve also got just over 200k shares and intend to hold for the foreseeable. BBSN was at 5p two years ago and there have been no placings since then, the business strategy is starting to bear fruit & we have a great CEO & CFO who have a track record of success. All that’s needed is a medium term hold and if you’ve done your research, it’s much easier to do so!
I think releasing a positive RNS and folllowing it up with a discounted placing is a great way to alienate any new shareholders that had been spiked! Great news and a very refreshing was of releasing it - no negatives as far as I can see, especially with a director buy of that size!
The key message from the video is that momentum is strong; a snowball effect trieggered by the Merck agreement. I also like the fact that Dr Jim Millen was a deal closing specialist prior to leaving big pharma for PYC - it’s clear these skills are playing a part in the step change in new business. The bottom line is that this company is doing its utmost to assist in the battle against cancer, and has performed very strongly over the past 6 months, both in share price and business development. These are undisputable facts, and in my opinion there is a long way to go here.
Applegarth, glad to provide some support and positivity! I can’t think why anyone would write so many negative posts every day over a period of months unless they were being paid to do so, or had a vendetta against the company. Potnak, if your cut and paste scenario came true and PYC had revenues of 2m, that would be an increase of over 7x year on year and undoubtedly see them turn a decent profit. Time will tell, but given the step change in activity post finalising the Merck Master Services Agreement combined with industry trends towards personalised medicines, I think the furtive looks very bright.
Prior to the November announcement, the PYC market cap was around £500k, and as the agreement with Merck is worth €500k per annum, it was no surprise that the share price went crazy. Since then, on 26th Jan and 9th Feb PYC have announced they have commenced projects for 35k and 70k with a major pharma and a global top 10 pharma, who are unnamed at present. PYC have a validated business model, do not obviously require funding, are working with two top 10 global pharma’s, and have a market cap of £3.9m. Any argument as to whether the share price should be 3p, 4p 5p or less is irrelevant unless you are a short term trader or shorter. If you have a time horizon of >6months the potential upside here is far greater, and as such a 5% allocation in my portfolio is a no brainer. Re the 2014 RNS announcing Merck as a partner, how much of this news was priced in with the market cap at 500k? My opinion; absolutely none of it.
Prior to the November announcement, the PYC market cap was around £500k, and as the agreement with Merck is worth €500k per annum, it was no surprise that the share price went crazy. Since then, on 26th Jan and 9th Feb PYC have announced they have commenced projects for 35k and 70k with a major pharma and a global top 10 pharma, who are unnamed at present. PYC have a validated business model, do not obviously require funding, are working with two top 10 global pharma’s, and have a market cap of £3.9m. Any argument as to whether the share price should be 3p, 4p 5p or less is irrelevant unless you are a short term trader or shorter. If you have a time horizon of >6months the potential upside here is far greater, and as such a 5% allocation in my portfolio is a no brainer. Re the 2014 RNS announcing Merck as a partner, how much of this news was priced in with the market cap at 500k? My opinion; absolutely none of it.
First post here but have been following this share closely since the incredible rise in November 17. I felt compelled to reply to the absolute garbage posted by Daveavt to try and prevent his lies becoming accepted as the truth, which is clearly what he intends. The November RNS that prompted the rise over 3 days from 1p to a 30p intraday high (closed at 17p) was prompted by PYC disclosing for the FIRST TIME that they had been working with Merck for a number of years on several projects. Prior to this announcement, PYC market cap was around £500k, and as the agreement with Merck was worth a minimum of £500k per annum, it was no surprise that the share price went crazy. Since then, on 26th Jan and 9th Feb PYC have announced they have commenced projects for 35k and 70k with a major pharma and a global top 10 pharma, who are unnamed at present, in the same way that Merck was prior to their unveiling in November. I’m not going to state my opinion of what would happen if either of these two pharma’s commit to a long term contact a la Merck, as apparently that would be ramping... However, I will state that PYC have a validated business model, do not obviously require funding, are working with two top 10 global pharma’s, and have a market cap of £3.9m. Any argument as to whether the share price should be 3p, 4p 5p or less is irrelevant unless you are a short term trader or shorter. If you have a time horizon of >6months the potential upside here is far greater, and as such a 5% allocation in my portfolio is a no brainer. Last bit for Daveavt, I will post this as a reply to every one of your negative comments until you stop your campaign of hate, it has gone on for far too long.